- Home
- CAN vs CBLL Comparison
CAN vs CBLL Comparison
Compare CAN & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAN | CBLL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 428.8M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CAN | CBLL |
|---|---|---|
| Price | $0.79 | $21.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $3.56 | ★ $25.17 |
| AVG Volume (30 Days) | ★ 27.3M | 596.0K |
| Earning Date | 11-18-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,228,000.00 | $82,813,000.00 |
| Revenue This Year | $91.42 | $37.43 |
| Revenue Next Year | $47.07 | $27.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.87 | 37.93 |
| 52 Week Low | $0.53 | $10.01 |
| 52 Week High | $3.27 | $32.75 |
Technical Indicators
Market Signals| Indicator | CAN | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 79.60 |
| Support Level | $0.91 | $19.87 |
| Resistance Level | $0.93 | $24.25 |
| Average True Range (ATR) | 0.06 | 1.10 |
| MACD | -0.00 | 0.31 |
| Stochastic Oscillator | 5.15 | 68.41 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.